Table 2.
Diagnostic performance of the molecular parameters among the study groups.
| Test Result Variable(s) | Area | Std. Error | Asymptotic Sig. | Asymptotic 95% Confidence Interval | Cutoff | Sensitivity | Specificity | |
|---|---|---|---|---|---|---|---|---|
| Lower Bound | Upper Bound | |||||||
| NAFLD/NASH vs. Control | ||||||||
| lncRNA RABGAP1L-DT-206 | 0.844 | 0.031 | 0.000 | 0.82 | 0.905 | 4.8 | 81% | 83% |
| has-miR-mir-6888-5p | 0.916 | 0.019 | 0.000 | 0.879 | 0.953 | 1.97 | 91% | 77% |
| EDN1mRNA | 0.797 | 0.033 | 0.000 | 0.731 | 0.862 | 1.85 | 87% | 70% |
| EP300 mRNA | 0.839 | 0.031 | 0.000 | 0.779 | 0.900 | 2.15 | 83% | 80% |
| MAPK3 mRNA | 0.871 | 0.026 | 0.000 | 0.820 | 0.921 | 2.65 | 88% | 73% |
| TNF mRNA | 0.841 | 0.031 | 0.000 | 0.781 | 0.901 | 2.05 | 82% | 81% |
| Combined RNAs | 0.888 | 0.022 | 0.000 | 0.923 | 0.845 | 3.25 | 91% | 73% |
| AST | 0.653 | 0.039 | 0.000 | 57 | 0.577 | 0.729 | 55% | 72% |
| ALT | 0.669 | 0.039 | 0.000 | 27 | 0.593 | 0.745 | 57% | 73% |
| GGT | 0.806 | 0.030 | 0.000 | 39.5 | 0.748 | 0.864 | 66% | 71% |
| Group A vs. Group B | ||||||||
| lncRNA RABGAP1L-DT-206 | 0.944 | 0.038 | 0.000 | 3.4 | 0.869 | 1 | 100% | 79% |
| hsa-mir-6888-5p | 0.628 | 0.097 | 0.197 | 3.6 | 0.438 | 0.819 | 50.7% | 69.6% |
| EDN1mRNA | 0.648 | 0.097 | 0.136 | 4.1 | 0.457 | 0.839 | 62.5% | 64.5% |
| EP300 mRNA | 0.707 | 0.089 | 0.037 | 2.3 | 0.533 | 0.832 | 81.3% | 58.9% |
| MAPK3 mRNA | 0.729 | 0.088 | 0.021 | 4.05 | 0.556 | 0.901 | 68.8% | 58.9% |
| TNF mRNA | 0.727 | 0.089 | 0.022 | 2.3 | 0.561 | 0.893 | 75.3% | 58.9% |